BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jung YS, Han M, Park S, Cheon JH. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. Dig Dis Sci 2020;65:1436-44. [PMID: 31677070 DOI: 10.1007/s10620-019-05867-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Frasca JD, Cheifetz AS. The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth. Ann Transl Med 2019;7:S388. [PMID: 32016106 DOI: 10.21037/atm.2019.12.86] [Reference Citation Analysis]
2 Miyazaki C, Katsumasa N, Huang KC, Liu YF. Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan. PLoS One 2021;16:e0254807. [PMID: 34280242 DOI: 10.1371/journal.pone.0254807] [Reference Citation Analysis]
3 Bargo D, Tritton T, Cappelleri JC, DiBonaventura M, Smith TW, Tsuchiya T, Gardiner S, Modesto I, Holbrook T, Bluff D, Kobayashi T. Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use. Inflamm Intest Dis 2021;6:186-98. [PMID: 35083284 DOI: 10.1159/000519123] [Reference Citation Analysis]